ScholarLens Back to search
2011•Neuromuscular DisordersRequires access

Amyotrophic Lateral Sclerosis

Amy Chen, Hiroshi Mitsumoto

Open publisher page 6 citations

Abstract

Amyotrophic lateral sclerosis (ALS) is primarily a disease of motor neuron degeneration that causes progressive muscle atrophy and leads to respiratory failure and eventual death in 3–5 years from the time of symptom onset. The cause of the disease remains mostly unknown. Diagnosis is based on clinical and electrophysiological evaluation. Riluzole is the only drug approved by the US Food and Drug Administration for treating ALS. Management of the disease requires multidisciplinary care.

About this research paper

What this paper is about

Amyotrophic lateral sclerosis (ALS) is primarily a disease of motor neuron degeneration that causes progressive muscle atrophy and leads to respiratory failure and eventual death in 3–5 years from the time of symptom onset. The cause of the disease remains mostly unknown. Diagnosis is based on clinical and electrophysiological evaluation. Riluzole is the only drug approved by the US Food and Drug Administration for treating ALS. Management of the disease requires multidisciplinary care.

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Amyotrophic lateral sclerosis (ALS) is primarily a disease of motor neuron degeneration that causes progressive muscle atrophy and leads to respiratory failure and eventual death in 3–5 years from the time of symptom onset. The cause of the disease remains mostly unknown. Diagnosis is based on clinical and electrophysiological evaluation. Riluzole is the only drug approved by the US Food and Drug Administration for treating ALS. Management of the disease requires multidisciplinary care.

Key concepts: Amyotrophic lateral sclerosis, Physical medicine and rehabilitation, Neuroscience, Medicine, Psychology, Internal medicine, Disease

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Amyotrophic Lateral Sclerosis — Research Paper | ScholarLens